Our findings suggest that BRAF600E and some KRAS mutant colon cancers are unlikely to respond to mono therapy targeting mTOR, but might benefit from combination therapy with BH3 mimetics, or inhibitors of PI3K, Raf or MEK. Here, PIK3CA is linked to malignant colon neoplasm.